0000950170-24-069401.txt : 20240605
0000950170-24-069401.hdr.sgml : 20240605
20240605165319
ACCESSION NUMBER: 0000950170-24-069401
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240603
FILED AS OF DATE: 20240605
DATE AS OF CHANGE: 20240605
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Scott Randal W.
CENTRAL INDEX KEY: 0001337801
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38959
FILM NUMBER: 241022724
MAIL ADDRESS:
STREET 1: 171 MAIN STREET #225
CITY: LOS ALTOS
STATE: CA
ZIP: 94022
FORMER NAME:
FORMER CONFORMED NAME: Scott Randal W
DATE OF NAME CHANGE: 20050901
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BridgeBio Pharma, Inc.
CENTRAL INDEX KEY: 0001743881
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3160 PORTER DR.
STREET 2: SUITE 250
CITY: PALO ALTO
STATE: CA
ZIP: 94304
BUSINESS PHONE: (650) 391-9740
MAIL ADDRESS:
STREET 1: 3160 PORTER DR.
STREET 2: SUITE 250
CITY: PALO ALTO
STATE: CA
ZIP: 94304
FORMER COMPANY:
FORMER CONFORMED NAME: BridgeBio Pharma LLC
DATE OF NAME CHANGE: 20180618
4
1
ownership.xml
4
X0508
4
2024-06-03
0001743881
BridgeBio Pharma, Inc.
BBIO
0001337801
Scott Randal W.
C/O BRIDGEBIO PHARMA, INC.
3160 PORTER DR., SUITE 250
PALO ALTO
CA
94304
true
false
false
false
true
Common Stock
2024-06-03
4
S
false
800
28.6844
D
5700
I
By Thinking Bench Capital LLC
Common Stock
2024-06-03
4
S
false
200
29.475
D
5500
I
By Thinking Bench Capital LLC
Common Stock
2024-06-04
4
S
false
1500
31.30
D
4000
I
By Thinking Bench Capital LLC
Common Stock
5000
D
This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by Thinking Bench Capital LLC on June 6, 2023.
Represents the weighted average sale price of the shares sold ranging from $28.31 to $29.24 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Represents the weighted average sale price of the shares sold ranging from $29.44 to $29.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
/s/ Brian C. Stephenson, Attorney-in-Fact
2024-06-05